In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...